Pharmacokinetics of pulse-sprayed recombinant tissue plasminogen activator for deep venous thrombosis.
Horne
McDonald K
MK
Department of Laboratory Medicine, W.G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. mhorne@mail.cc.nih.gov
Chang
Richard
R
D004334:Drug Administration Schedule; D005338:Fibrin Fibrinogen Degradation Products / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D010958:Plasminogen / Q000378:metabolism; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000979:alpha-2-Antiplasmin / Q000378:metabolism
D005338:Fibrin Fibrinogen Degradation Products; D011994:Recombinant Proteins; D000979:alpha-2-Antiplasmin; C036309:fibrin fragment D; D005340:Fibrinogen; D010958:Plasminogen; D010959:Tissue Plasminogen Activator